Cargando…
Continuum Crystallization Model Derived from Pharmaceutical Crystallization Mechanisms
[Image: see text] The crystallization mechanisms of organic molecules in solution are not well-understood. The mechanistic scenarios where crystalline order evolves directly from the molecularly dissolved state (“classical”) and from initially formed amorphous intermediates (“nonclassical”) are sugg...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161475/ https://www.ncbi.nlm.nih.gov/pubmed/34079905 http://dx.doi.org/10.1021/acscentsci.1c00254 |
_version_ | 1783700519617822720 |
---|---|
author | Tsarfati, Yael Biran, Idan Wiedenbeck, Eduard Houben, Lothar Cölfen, Helmut Rybtchinski, Boris |
author_facet | Tsarfati, Yael Biran, Idan Wiedenbeck, Eduard Houben, Lothar Cölfen, Helmut Rybtchinski, Boris |
author_sort | Tsarfati, Yael |
collection | PubMed |
description | [Image: see text] The crystallization mechanisms of organic molecules in solution are not well-understood. The mechanistic scenarios where crystalline order evolves directly from the molecularly dissolved state (“classical”) and from initially formed amorphous intermediates (“nonclassical”) are suggested and debated. Here, we studied crystallization mechanisms of two widely used analgesics, ibuprofen (IbuH) and etoricoxib (ETO), using direct cryogenic transmission electron microscopy (cryo-TEM) imaging. In the IbuH case, parallel crystallization pathways involved diverse phases of high and low density, in which the instantaneous formation of final crystalline order was observed. ETO crystallization started from well-defined round-shaped amorphous intermediates that gradually evolved into crystals. This mechanistic diversity is rationalized by introducing a continuum crystallization paradigm: order evolution depends on ordering in the initially formed intermediates and efficiency of molecular rearrangements within them, and there is a continuum of states related to the initial order and rearrangement rates. This model provides a unified view of crystallization mechanisms, encompassing classical and nonclassical pictures. |
format | Online Article Text |
id | pubmed-8161475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-81614752021-06-01 Continuum Crystallization Model Derived from Pharmaceutical Crystallization Mechanisms Tsarfati, Yael Biran, Idan Wiedenbeck, Eduard Houben, Lothar Cölfen, Helmut Rybtchinski, Boris ACS Cent Sci [Image: see text] The crystallization mechanisms of organic molecules in solution are not well-understood. The mechanistic scenarios where crystalline order evolves directly from the molecularly dissolved state (“classical”) and from initially formed amorphous intermediates (“nonclassical”) are suggested and debated. Here, we studied crystallization mechanisms of two widely used analgesics, ibuprofen (IbuH) and etoricoxib (ETO), using direct cryogenic transmission electron microscopy (cryo-TEM) imaging. In the IbuH case, parallel crystallization pathways involved diverse phases of high and low density, in which the instantaneous formation of final crystalline order was observed. ETO crystallization started from well-defined round-shaped amorphous intermediates that gradually evolved into crystals. This mechanistic diversity is rationalized by introducing a continuum crystallization paradigm: order evolution depends on ordering in the initially formed intermediates and efficiency of molecular rearrangements within them, and there is a continuum of states related to the initial order and rearrangement rates. This model provides a unified view of crystallization mechanisms, encompassing classical and nonclassical pictures. American Chemical Society 2021-04-23 2021-05-26 /pmc/articles/PMC8161475/ /pubmed/34079905 http://dx.doi.org/10.1021/acscentsci.1c00254 Text en © 2021 The Authors. Published by American Chemical Society Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Tsarfati, Yael Biran, Idan Wiedenbeck, Eduard Houben, Lothar Cölfen, Helmut Rybtchinski, Boris Continuum Crystallization Model Derived from Pharmaceutical Crystallization Mechanisms |
title | Continuum Crystallization Model Derived from Pharmaceutical
Crystallization Mechanisms |
title_full | Continuum Crystallization Model Derived from Pharmaceutical
Crystallization Mechanisms |
title_fullStr | Continuum Crystallization Model Derived from Pharmaceutical
Crystallization Mechanisms |
title_full_unstemmed | Continuum Crystallization Model Derived from Pharmaceutical
Crystallization Mechanisms |
title_short | Continuum Crystallization Model Derived from Pharmaceutical
Crystallization Mechanisms |
title_sort | continuum crystallization model derived from pharmaceutical
crystallization mechanisms |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161475/ https://www.ncbi.nlm.nih.gov/pubmed/34079905 http://dx.doi.org/10.1021/acscentsci.1c00254 |
work_keys_str_mv | AT tsarfatiyael continuumcrystallizationmodelderivedfrompharmaceuticalcrystallizationmechanisms AT biranidan continuumcrystallizationmodelderivedfrompharmaceuticalcrystallizationmechanisms AT wiedenbeckeduard continuumcrystallizationmodelderivedfrompharmaceuticalcrystallizationmechanisms AT houbenlothar continuumcrystallizationmodelderivedfrompharmaceuticalcrystallizationmechanisms AT colfenhelmut continuumcrystallizationmodelderivedfrompharmaceuticalcrystallizationmechanisms AT rybtchinskiboris continuumcrystallizationmodelderivedfrompharmaceuticalcrystallizationmechanisms |